BioGend Therapeutics Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Millions TWD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	562.3	217.9	219.02	330.51	163.64	136.32
Short-Term Investments	300	300	400	393.76	329.76	552.96
Cash & Short-Term Investments	862.3	517.9	619.02	724.27	493.4	689.28
Cash Growth	47.31%	-16.34%	-14.53%	46.79%	-28.42%	34.36%
Accounts Receivable	58.57	58.96	47.36	26.69	11.27	5.05
Other Receivables	1.35	32.18	33.37	30.67	28.25	23.61
Receivables	59.92	91.14	80.72	57.36	39.52	28.66
Inventory	28	20.52	15.96	16.55	4.9	9.03
Prepaid Expenses	32.23	6.87	2	3	4.07	7.57
Total Current Assets	982.45	636.43	717.7	801.18	541.89	734.54
Property, Plant & Equipment	40.86	43.11	49.57	56.2	34.01	8.89
Long-Term Investments	7.35	7.65	8.33	20.34	10	-
Goodwill	-	17.09	17.09	17.09	17.09	17.09
Other Intangible Assets	80.3	73.26	114.07	151.04	210.95	261.92
Other Long-Term Assets	38.79	37.85	5.94	4.64	7.89	1.42
Total Assets	1,150	815.38	912.7	1,050	821.82	1,024
Accounts Payable	2.49	2.09	4.22	2.16	2.08	0.49
Accrued Expenses	-	27.03	22.29	16.57	17.22	14.39
Current Portion of Leases	3.79	3.73	3.59	3.65	3.49	3.94
Other Current Liabilities	22.31	3.31	3.13	23.87	9.07	6.3
Total Current Liabilities	28.58	36.16	33.23	46.25	31.86	25.13
Long-Term Leases	1.92	2.85	5.84	9.44	12.28	0.48
Long-Term Unearned Revenue	-	-	-	2.5	2.5	2.5
Long-Term Deferred Tax Liabilities	16.63	18.73	27.13	35.52	43.92	52.31
Total Liabilities	47.14	57.74	66.19	93.71	90.56	80.42
Common Stock	1,244	1,244	1,243	1,231	1,031	1,031
Additional Paid-In Capital	261.46	-	-	-	-	212.85
Retained Earnings	-498.72	-482.93	-398.32	-281.85	-325.52	-353.91
Comprehensive Income & Other	82.1	-18.54	-26.58	-7.96	-2.38	-2.16
Total Common Equity	1,088	742.09	817.67	940.96	702.86	887.54
Minority Interest	14.21	15.55	28.84	15.81	28.4	55.91
Shareholders' Equity	1,103	757.64	846.51	956.77	731.27	943.45
Total Liabilities & Equity	1,150	815.38	912.7	1,050	821.82	1,024
Total Debt	5.71	6.58	9.43	13.09	15.77	4.42
Net Cash (Debt)	856.59	511.33	609.59	711.18	477.64	684.86
Net Cash Growth	48.50%	-16.12%	-14.28%	48.90%	-30.26%	33.49%
Net Cash Per Share	6.89	4.15	4.95	5.91	4.63	6.76
Filing Date Shares Outstanding	124.36	124.36	124.26	123.08	103.08	103.08
Total Common Shares Outstanding	124.36	124.36	124.26	123.08	103.08	103.08
Working Capital	953.87	600.27	684.47	754.93	510.03	709.42
Book Value Per Share	8.75	5.97	6.58	7.65	6.82	8.61
Tangible Book Value	1,008	651.75	686.51	772.83	474.82	608.52
Tangible Book Value Per Share	8.11	5.24	5.52	6.28	4.61	5.90
Machinery	-	33.26	31.6	31.19	24.66	24.55
Construction In Progress	-	-	-	37.57	14.91	-
Leasehold Improvements	-	38.15	38.15	0.34	0.34	0.34

Source: S&P Global Market Intelligence. Standard template. Financial Sources.